AI Clinical Trial Endpoint Tool Gains Regulatory Approval
zakkohane · x · 2026-07-19
A new Perspective article discusses the significance of an AI-enabled clinical trial endpoint tool (AIM-NASH) receiving recognition from the European Medicines Agency and the US FDA.
The accompanying image lists various potential AI applications in clinical trial endpoints, including:
- Pathology, imaging, physiological imaging as surrogate endpoints
- Symptom reports, functional assessments, event classification as clinical endpoints
- Using sensors, smartphones, and AI classification models to improve data collection and endpoint adjudication consistency
The article focuses not on a single model, but on how such tools change clinical evidence generation and endpoint adjudication processes.
More from Safety
- Ben Bajarin: Frontier AI Labs Are Becoming the Enterprise Cyber-Defense Stack — BenBajarin · 2026-10-26
- DetectorScope turns black-box AI text detectors into auditable ones with sparse autoencoders — _akhaliq · 2026-10-26
- Anthropic's IPO filing devotes 94 pages to existential AI risks, from self-preservation to blackmail — Polymarket · 2026-10-26
- Study finds AI reviewing AI poorly detects reward hacking; comprehension audits proposed — ronbodkin · 2026-10-26
- A 13KB Markdown file can hijack Claude Code and Codex via your Downloads folder — pbaylies · 2026-10-26
- If an agent can rewrite itself, does your consent still mean anything? — tallmetommy · 2026-10-26